Levodopa is the most effective and widely used agent available for Parkinson's disease. Entacapone and carbidopa are enzyme-blocking compounds that enhance the therapeutic benefits of levodopa.
At the start of levodopa treatment, the effect of levodopa lasts for many hours. However, even within just two years approximately 40 percent of patients begin to notice that their levodopa lasts for shorter periods of time, a phenomenon known as "wearing off". Eventually, the effect of a levodopa dose may decrease to only one to two hours. Most Parkinson's disease patients will experience "wearing off" and in many patients, "wearing off" becomes increasingly disabling during the course of disease.
"With Stalevo we can enhance the benefits of levodopa and more effectively treat the problems such as "wearing off" that complicate the long-term use of levodopa and limit its utility. Stalevo thus represents an important advance in our ability to treat Parkinson's disease patients", said professor David Brooks, one of the leading Stalevo investigators, at the Medical Research Council Clinical Sciences Centre and Imperial College London, UK.
The effectiveness of levodopa, carbidopa and entacapone in the treatment of Parkinson's has been established in multicenter, randomised, double blind placebo-controlled trials in patients experiencing "wearing off". The components of Stalevo were shown to increase the period where patients experience no symptoms and improve motor function and daily activities such as patients' ability to walk, dress, and maintain hygiene. In addition, in a separate study, most patients regarded Stalevo as easy to dose, use, handle and swallow.
In all studies Stalevo was well tolerated, the most commonly reported adverse events being uncontrolled movements (dyskinesias) and nausea. The side effects are generally mild to moderate in nature and if they occur, they can usually be managed with dose modifications. Side effects seldom lead to treatment discontinuation.
Stalevo is a significant new product introduction from the R&D pipeline of Orion Pharma. Orion is the originator and manufacturer of entacapone, the leading COMT-inhibitor used as an important adjunct to levodopa in the treatment of PD. Entacapone was launched in 1998-1999 world-wide as Comtess and Comtan, and it soon became Orion's best-selling brand.
Stalevo will be available in Europe from Orion Pharma and Novartis. Orion's territories include Germany, UK and Ireland, all the Nordic countries, and the Baltic states. The other markets are licensed to Novartis, which is also the marketer of entacapone under the name Comtan. Orion will receive a milestone payment of USD 5 million from Novartis triggered by the EU marketing authorisation.
Jukka Viinanen Risto Miettunen
President and CEO, Orion Group President, Orion Pharma
Timo Lappalainen, Senior Vice President, Orion Pharma, phone +358 50 429 3692
Esa Heinonen, Vice President, Research and Development, Orion Pharma, phone +358 50 429 4302
About Parkinson's disease
Parkinson's disease, a chronic and progressive neurological condition, affects more than 1% of people over 65 years old. While its cause is unknown, Parkinson's results from a destruction of dopaminergic cells, or neurons, in the substantia nigra, a part of the brain that controls movement. Symptoms include limbs that tremble when relaxed; slowness of movement; stiffness and rigidity of limbs and gait or balance problems. As the disease progresses, these symptoms usually increase and impact a person's ability to work and function.
Orion Pharma is a research and development-orientated pharmaceutical division of the Orion Group (HEX:ORIA, ORIB), which is one of the leading companies in the healthcare sector in the Nordic area of Europe. Pharmaceutical R&D at Orion Pharma focuses on three core therapy areas: CNS therapies, cardiology and critical care, and hormonal therapies. Entacapone, a COMT enzyme inhibitor used in the treatment of Parkinson's disease, is Orion Pharma's patented molecule discovery, available globally as Comtess and Comtan. For further information please consult http://www.orion.fi
Orionintie 1, 02200 Espoo
Heikki Vuonamo, Corporate VP, Communications
Phone +358 10 429 4967
Fax +358 10 429 4435